Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Exclusion Criteria

• •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing.
• •History of allergic reactions to diagnostic or therapeutic protein or human albumin.
• •History of recurrent infections or active infection within 28 days of screening.
• •Exposure to live vaccines within 28 days of screening.
• •History of regular alcohol consumption or positive drug test
• •Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of IP (whichever is longer).
• •Fertile male subjects who are unwilling or unable to use a highly effective method of contraception for the duration of the study and for at least 28 days after the last dose.
• •Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose